New drug with chemotherapy before and after pancreatic cancer surgery
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new drug (NP137) combined with the chemotherapy FOLFIRINOX before and after surgery for people with pancreatic cancer that can be removed. The goal is to see if this combination helps prevent the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that a surgeon believes can be completely removed.
- You have not had any chemotherapy, radiation, or surgery for this cancer before.
- You are at least 18 years old and in good enough health to undergo treatment (ECOG score 0-1).
- Your blood and organ function must be adequate (your doctor will check this).
- If you could become pregnant, you must have a negative pregnancy test and use effective birth control during and for 6 months after treatment.
- You must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy drugs (NALIRIFOX) given before and after surgery for people with pancreatic cancer that is at high risk of coming back but can still be surgically removed. The goal is to see if this treatment helps improve outcomes.
This trial tests a new chemotherapy combination (HR070803 plus two other drugs) given after surgery to see if it prevents pancreatic cancer from coming back better than the current standard treatment.
This trial tests a new drug combination given before surgery for pancreatic cancer that has not spread. It includes targeted therapy, chemotherapy, and possibly immunotherapy to see if it can shrink tumors and improve outcomes.
This trial uses a special gene test on fluid taken from an endoscopic ultrasound (EUS) biopsy to help choose chemotherapy before surgery for pancreas cancer. It aims to see if this approach improves outcomes by matching treatment to the tumor’s RNA pattern.
This Phase 2 study tests whether FOLFIRINOX given after pancreatic surgery can lower the chance the cancer comes back. It focuses on people with pancreatic ductal adenocarcinoma who had their tumor completely removed and have no spread to distant organs.
This clinical trial tests whether a combination of chemotherapy drugs (liposomal irinotecan, oxaliplatin, and S-1) is more effective than another standard chemotherapy combination (gemcitabine plus capecitabine) after surgery for pancreatic cancer. It aims to help prevent the cancer from coming back.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.